Aminotadalafil

Aminotadalafil, also written as amino-tadalafil or 2-aminotadalafil, is a synthetic analogue of tadalafil, the phosphodiesterase type 5 (PDE5) inhibitor marketed as Cialis. Chemically it is (6R,12aR)-2-amino-6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione, differing from tadalafil by replacement of the N-methyl group on the diketopiperazine ring with an amino group ^[1]. That close structural relationship places it in the same designer-analogue family created to mimic approved PDE5 inhibitors while evading detection and regulation.

Unlike tadalafil, aminotadalafil has never undergone formal pharmacological or clinical development, and essentially all of the published literature concerns its analytical detection rather than any therapeutic use. Investigators have repeatedly isolated and structurally confirmed aminotadalafil as an unapproved adulterant hidden in dietary supplements and herbal products sold for erectile dysfunction, using techniques such as HPLC, nuclear magnetic resonance, and high-resolution mass spectrometry ^[1][2][4]. It has also been characterized as a condensation product with excipients in an illegal health food ^[3] and identified alongside rimonabant in electronic cigarette cartridges ^[5], and it features in multi-analyte screening panels developed by public-health laboratories to police supplement adulteration ^[6].

Because it is an unapproved analogue, aminotadalafil holds no marketing authorization anywhere and is not a legitimate medicine; regulators treat its presence in consumer products as illegal adulteration posing an unquantified health risk ^[1]. It is encountered as a raw powder or as a hidden ingredient in tablets, capsules, and liquids, and its true potency, pharmacokinetics, and safety in humans remain uncharacterized ^[6].

Aminotadalafil is an unapproved analogue of the PDE5 inhibitor tadalafil that has been detected as an adulterant in some products; it shares PDE5-inhibitor pharmacology and is sold as a research chemical with no established human safety data. It can cause severe, potentially fatal hypotension when combined with nitrates or other vasodilators, and class risks include headache, flushing, visual disturbance, priapism, and hazard in cardiovascular disease. Because its potency and purity are uncharacterized, dosing risks are unpredictable.

Aminotadalafil is not a formally developed medicine but a synthetic analogue of tadalafil, the approved PDE5 inhibitor marketed as Cialis by Eli Lilly since 2003. Its documented history is analytical rather than clinical: it first entered the scientific record as an unapproved adulterant, notably when United States Food and Drug Administration scientists identified it, alongside the withdrawn weight-loss drug rimonabant, in electronic cigarette cartridges in a 2010 chromatography study. A closely related acetylated version, acetaminotadalafil, was subsequently detected in bulk powder destined for dietary supplements. No regulatory agency has approved aminotadalafil for human use, and there are no controlled trials of its safety, potency, or pharmacokinetics in people.

Aminotadalafil occupies an unusual position: it is well characterized as a chemical entity yet almost entirely unstudied as a therapeutic. Analytical chemists have documented it precisely, including high-resolution mass-spectrometry work that pins down its structure among designer PDE5 analogues, and it is by design expected to act on the same nitric-oxide and cGMP pathway as tadalafil. Honesty requires noting the flip side: because it is an unregulated research chemical rather than an approved drug, it lacks the dose accuracy, purity control, and human safety testing of a licensed medicine, and it carries the same class-related risks as approved inhibitors, including potentially dangerous drops in blood pressure if combined with nitrates. Its scientific interest lies chiefly in supplement surveillance and forensic identification.